HISTORIC DEVELOPMENT OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE CLASSIFICATION
https://doi.org/10.21292/2075-1230-2018-96-1-51-56
Abstract
The article describes the history of the classification of chronic obstructive pulmonary disease, which leads to Global Initiative for Obstructive Lung Disease ‒ GOLD, a document describing all aspects of this disease which are currently known.
About the Authors
A. V. Nikitin
Voronezh State Medical University named after N.N. Burdenko
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Head of Propedeutics of Internal Diseases Department
10, Studencheskaya St., Voronezh, 394036 Phone: +7 (473) 236-68-31
L. V. Vasilyeva
Voronezh State Medical University named after N.N. Burdenko
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Head of Therapy Department
10, Studencheskaya St., Voronezh, 394036 Phone: +7 (473) 236-68-31
E. P. Karpukhina
Voronezh State Medical University named after N.N. Burdenko
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor of Propedeutics of Internal Diseases Department
10, Studencheskaya St., Voronezh, 394036 Phone: +7 (473) 236-68-31
E. M. Tolstykh
Voronezh State Medical University named after N.N. Burdenko
Russian Federation
Russian Federation
Candidate of Medical Sciences, Assistant of Propedeutics of Internal Diseases Department
10, Studencheskaya St., Voronezh, 394036 Phone: +7 (473) 236-68-31
References
1. Аysanov Z.R., Аvdeev S.N., Аrkhipov V.V., Belevskiy А.S., Leschenko I.V., Ovcharenko S.N., Shmelev E.I., Chuchalin А.G. Federal clinical recommendations on diagnostics and treatment of chronic obstructive pulmonary disease: procedure for making clinical decisions. Pulmonoloiya, 2017, vol. 27, no. 1, pp. 13-20. (In Russ.)
2. Chuchalin A.G. Chronic obstructive lung disease and concurrent conditions. Pulmonoloiya, 2008, 2, pp. 5-14. (In Russ.)
3. Agusti A., Calverley P.M., Celli B. et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res., 2010, vol. 11, pp. 122.
4. Barnes P.J., Adcock I.M. Glucocorticosteroid resistance in inflammatory diseases. Lancet, 2009, vol. 373, pp. 1905-1913.
5. Bestall J.C., Paul E.A., Garrod R., Gamham R., Jones P.W., Wedzicha J.A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax, 1999, vol. 54, pp. 581-586.
6. Burrows B., Fletcher C.M., Heard B.E., Jones N.L., Wootliff J.S. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet, 1966, vol. 87, pp. 830-835.
7. Calverley P.M., Anderson J.A., Celly B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med., 2007, vol. 356, pp. 775-789.
8. Dodd J.W., Hogg I., Nolan J. et al. The COPD Assessment Test (CAT): response to pulmonary rehabilitation. A multicenter, prospective study. Thorax, 2011, vol. 66, pp. 425-434.
9. Donaldson G.C., Seemungal T.A., Bhowmik A. et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, vol. 57, pp. 847-852.
10. Global Initiative for Chronic Obstructive Lung Diseases. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. (Revised 2011) Rossiyskoye Respiratornoye Obschestvo Publ., 2012.
11. Global Initiative for Chronic Obstructive Lung Diseases. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. (Revised 2013).
12. Groenewegen K.H., Schols A.M.W.J., Wouters E.F.M. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest, 2003, vol. 124, pp. 459-467.
13. Hatzelmann A., Morcillo E.J., Lungarella G. et al. The preclinical pharmacology of roflumilast selective oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulmonary Pharm. Therapeutics, 2010, vol. 23, pp. 235-256.
14. Jones P.W., Harding G., Berry P., Wiklund I., Chen W.H., Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur. Respir. J., 2009, vol. 34, pp. 648-702.
15. Keatings V.M., Jatakanon A., Worsde Y.M. et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med., 1997, vol. 155, pp. 542-548.
16. Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest, 2002, vol. 121, pp. 1434-1449.
17. Pauwels R.A., Buist A.S., Calverley P.M. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med., 2001, vol. 163, pp. 1256-1276.
18. Rabe K.F., Hurd S., Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med., 2007, vol. 176, pp. 532-555.
19. Reda A.A., Kotz D., Kocks J.W., Wesseling G., van Schayck C.P. Reliability and validity of the clinical COPD questionnaire and the chronic respiratory questionnaire. Respir. Med., 2010, vol. 104, no. 11, pp. 1675-1682.
20. Seemungal T.A., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 1998, vol. 157, pp. 1418-1422.
21. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax, 2005, vol. 60, pp. 925-931.
22. Thurlbeck W.M. Chronic bronchitis and emphysema. Med. Clin. North. Am., 1973, vol. 57, pp. 651-668.
23. Trappenburg J.C., Touwen I., de Weert-van Oene G.H., Bourbeau J., Monnikhof E.M., Verheij et al. Detecting exacerbation using the Clinical COPD Questionnaire. Health Qual. Life Outcomes, 2010, vol. 8, pp. 102.
24. Van der Molen T., Willemse B.W., Schokker S., ten Hacken N.H., Postma D.S., Juniper E.F. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual. Life Outcomes, 2003, vol. 1, pp. 13.
25. Vogelmeier C.F., Criner G.J., Martinez F.J., Anzueto A., Barnes P.J., Bourbeau J., Celli B.R., Chen R., Decramer M., Fabbri L.M., Frith P. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am. J. Respir. Crit. Care Med., 2017, vol. 195, no. 5 , Mar 01, 2017. DOI: http://dx.doi. org/10.1164/rccm.201701-0218PP.
26. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet, 2007, vol. 370, pp. 786-796.
Review
For citations:
Nikitin A.V., Vasilyeva L.V., Karpukhina E.P., Tolstykh E.M. HISTORIC DEVELOPMENT OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE CLASSIFICATION. Tuberculosis and Lung Diseases. 2018;96(1):51-56. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-1-51-56
Views:
2636
Email this article 